Archives: 2021-11-20

PIER MARIA FORNASARI
2021-11-20

UCalgary study shows how desamethasone, used to treat critically ill COVID-19 patients, modulates immature neutrophils and interferon programming and why drug may only benefit males

Research into the way our immune systems respond to COVID-19 reveals the sex of a patient may affect how well drugs work Anew study from the University of Calgary shows how dexamethasone, the main treatment for severe COVID-19 lung infections, alters how immune cells work, which may help male patients, but has little to no benefit for

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-11-19

New analysis predicts how well vaccines will work against COVID-19 strains

Vaccines are less effective against some COVID-19 variants and boosting may be required within one year to maintain efficacy above 50 per cent, according to a new study. The researchers from the Sydney Institute for Infectious Diseases at the University of Sydney, UNSW Sydney’s Kirby Institute and the University of Melbourne’s Doherty Institute have conducted an analysis

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-11-18

Early Convalescent Plasma for High-Risk Outpatients with Covid-19: results of a new trial published in NEJM confirm failure

The object of the study was to verify if early administration of convalescent plasma obtained from blood donors who have recovered from coronavirus disease 2019 (Covid-19) could prevent disease progression in acutely ill, high-risk patients with Covid-19. In this randomized, multicenter, single-blind trial, we assigned patients who were being treated in an emergency department for

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-11-18

Gene therapy effective in children with severe Hurler’s syndrome: the treatment, developed by SR-Tiget in Milan published in NEJM

The first tests on eight children show favorable preliminary results, with an adjustment of motor and cognitive skills and improvements in some brain and joint parameters Gene therapy takes steps forward in the fight against rare diseases. Eight children with severe Hurler’s syndrome, a disease associated with reduced life expectancy, benefited from this therapy. The

Read More

No Comments InGENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2021-11-17

First Data show Pfizer PF-07321332 Protease Inhibitor pill is effective in Preventing Severe COVID-19

Over the course of this pandemic, significant progress has been made in treating COVID-19 and helping to save lives. That progress includes the development of life-preserving monoclonal antibody infusions and repurposing existing drugs, to which NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership has made a major contribution. But for many months we’ve had hopes that a

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-11-17

Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy

Chimeric antigen receptor T-cell (CAR T) therapy has revolutionized the field of malignant hematology. CD19-targeted CAR T-cell therapy has resulted in effective, often durable, responses for chemotherapy-refractory B-cell lymphoma and B-acute lymphoblastic leukemia (B-ALL) in prospective clinical trials. CAR T cells against B-cell maturation antigen have also shown overall response rates in the range of

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2021-11-17

Monash University study uncovers a new understanding of how mesenchymal stromal cells benefit patients in cell therapy

The therapeutic benefit to patients receiving mesenchymal stromal cell (MSC) therapy is not because the injected cells remain viable, but because of cell death, researchers at the Monash Biomedicine Discovery Institute (BDI) have found. In recent years, significant efforts have been made to develop stem cell-based therapies for difficult-to-treat diseases. MSC therapy is regenerative cell-based

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2021-11-13

Low-molecular-weight heparin use in Covid-19 is associated with curtailed viral persistence: a retrospective multicentre observational study

Clotting problems and resulting complications are common in COVID-19 patients. Researchers at the Medical University of Vienna have now shown that a member of the anticoagulant group of drugs not only has a beneficial effect on survival of COVID-19 patients, but also influences the duration of active infection with the SARS-CoV-2 coronavirus. The results were

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-11-13

New research by Boston Children’s Hospital on ricolinostat repurposing to curb neutrophil extracellular traps (NETs) and to fight severe inflammation in Covid-19

As we’ve seen during the COVID-19 pandemic, serious infections sometimes trigger an excessive inflammatory reaction that does as much harm — or more — than the infection itself. New research at Boston Children’s Hospital and Brigham and Women’s Hospital suggests a potential way to block this hyperinflammation response by repurposing or modifying an existing drug.

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-11-12

Direct Comparison of Antibody Responses to Pfizer, Astrazeneca, Sputnik V and Sinopharm SARS-CoV-2 Vaccines in Mongolia: study published in Cell Host & Microbe by Stanford University

Different SARS-CoV-2 vaccines are approved in various countries, but few direct comparisons of the antibody responses they stimulate have been reported. In thi paper the authors collected plasma specimens in July 2021 from 196 Mongolian participants fully vaccinated with one of four COVID-19 vaccines: Pfizer/BioNTech, AstraZeneca, Sputnik V and Sinopharm. Functional antibody testing with a

Read More

No Comments InCovid-19